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ABSTRACT
Necrotizing enterocolitis (NEC) is a disease that predominantly affects preterm infants. Of the
10% of preterm neonates that develop NEC, about one in four cases results in death. The
pathophysiology presents as inflammation of intestinal epithelial cell lining and subsequent
tissue death, sometimes resulting in intestinal perforations. The underlying mechanisms have yet
to be comprehensively identified. Diagnosis--the rate limiting step in reducing critical
disease-onset-to-treatment time--is based on relatively nonspecific signs, impeding early and
accurate diagnosis. This project, a collaborative effort between Santa Clara and Stanford
Universities, aims to improve current diagnostic methods by identifying the first verifiable and
useful fecal biomarker for NEC. The primary molecule of interest is referenced as
“Candidate-X” to protect intellectual property. Stool samples from healthy and NEC-affected
infants at Stanford’s hospital, taken before and after treatment and analyzed at UC Davis,
showed a strong correlation between elevated Candidate-X levels and NEC. The effects of
Candidate-X and several other molecules on cell morphology were first studied in well plates
seeded with either human intestinal epithelial cells (HIEC-6) or human colon cancer cells
(HT-29). After HT-29 was verified as a biologically relevant cell line, two bacteria-related
factors of interest, butyrate and Candidate-X, were plated with HT-29 for further study. In light
of recent publications and unpublished data, Candidate-X was ultimately selected. Key results
show that Candidate-X causes a comparatively high level of cell death and its effects are
cell-correlated, suggesting a causative relationship between Candidate-X and NEC.
Morphological changes with Candidate-X treatment reveal an unidentified cell death pathway,
which will be the topic of future exploration. This paper proposes that using Candidate-X as a
noninvasive fecal biomarker in combination with current methods and predictive models may
improve speed and accuracy of NEC diagnosis, and outlines potential future directions for
research.

Keywords: Necrotizing Enterocolitis, NEC, Fecal Biomarker, Intestine, Preterm Infants,
Premature Infants, HT-29, HIEC-6, Morphology, Gut Dysbiosis, Fermentation Products
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Chapter 1: Introduction
1.1 Background
Human necrotizing enterocolitis (NEC) is an intestinal disease that predominantly affects
preterm neonates [1, 2, 3], or infants who have had a gestation period of less than 37 weeks [4].
About 10% of infants are born premature; NEC affects approximately one in ten of these infants
[1, 2]. Pathophysiology presents with inflammation of intestinal tissue upon feeding-induced
bacterial colonization of the gut, which can lead to tissue death, holes in the intestinal wall, and
in about one in four cases, fatality [2, 3]. While the precise and comprehensive etiology remains
undefined, the working theory for susceptibility is that it stems from a combination of genetic
factors and the premature intestinal environment, which may exist in a state of immaturity,
hyper-reactivity/sensitivity, and microbial imbalance [2].
Currently, NEC diagnosis in the early stages is based on relatively nonspecific clinical and
radiographic signs, some of which mimic sepsis [2, 6]. Infants are unable to communicate
symptoms such as pain levels and discomfort, so physicians are missing important information
that could help more efficiently diagnose the disease. This also makes studying the disease in
humans more difficult, compounding factors such as a premature infant’s fragility and size [6].
Treatment options for NEC are nonspecific as well [2]. The current standard of care includes
ceasing feeding; administering intravenous fluids, broad-spectrum antibiotics, and additional
oxygen or assisted breathing; and in severe (later-stage) cases, performing surgery [2, 3, 6, 7].
For cases requiring surgery, fatality rates for NEC rise to 50% [2, 7]; if the infant survives the
surgery, he/she will experience long-term health impacts [2, 3, 8]. This sobering statistic
emphasizes the importance of early diagnosis and treatment to a NEC infant’s survival and future
quality of life.
Improving current diagnostic methods and understanding of the disease would have a significant
impact on modern medicine’s ability to fight NEC because diagnosis is the rate limiting step in
reducing disease-onset-to-treatment time and understanding the disease is vital to discovering
better treatments. Through in vitro and in vivo (animal model or noninvasive human) disease
studies, researchers may accomplish this in the near future and pave the way for development of
more effective, NEC-specific treatment [5].
1.2 Review of the Field/Literature Search
An article by Neu and Walker published in the New England Journal of Medicine addresses that
current diagnostic methods need improvement [7]. Neu and Walker estimate NEC costs the
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United States healthcare system $500 million to $1 billion annually [7]. In agreement with other
sources [2, 3, 6], they state that the most common interventions for NEC are “abdominal
decompression, bowel rest, broad-spectrum intravenous antibiotics, and intravenous
hyperalimentation,” along with prebiotic and probiotic treatments [7]. Surgery is required for
patients who have intestinal perforations or other factors that render the disease stage severe [7].
Surgeries usually involve abdominal drainage, exploratory laparotomy that results in a resection
of the diseased bowel, and the creation of a stoma from an enterostomy [7]. Preterm infants with
NEC will on average be hospitalized 20 days longer than healthy preterm infants if no surgery is
required, and 60 days longer than healthy preterm infants if surgery is required [7]. Because of
the difficulties associated with diagnosing NEC, Neu and Walker note that a significant portion
of cases require surgery due to prolonged disease progression [7]. Spencer et al. states that one of
the most common severe long-term effects of NEC is short-bowel syndrome in pediatric patients,
on average costing an estimated $1.5 million over a 5-year period [8]. These sources highlight
the necessity of catching the disease early, as well as the significant cost (monetary, physical,
and psychological) that current standards of care present patients’ families, hospitals, and
insurance companies.
Sylvester et. al. offer an interesting supplement to traditional clinical diagnostics: predictive
models to assess risk and provide physicians with additional context for diagnosis [9]. The
Sylvester Lab previously conducted a retrospective analysis on 94,110 preterm births over a
3-year period with a validation cohort of 22,992 preterm births over a 1-year period to develop
their predictive model [9]. They were able to identify approximately 90% of NEC cases using the
model, demonstrating its efficacy [9]. Sylvester et al., and later, Sinclair et. al., both noted an
association between prematurity of infants, the development of NEC, and abnormal fatty acid
metabolism [5, 9]. Sylvester et. al. hypothesize that metabolic profiling may serve as a way to
objectively screen preterm infants for having or being at risk for developing NEC [9].
Furthermore, other sources note that certain acids known to be fermentation products of bacteria
can sometimes cause intestinal injury in rodent and human neonates, likely due to abnormal
metabolism of these products [5, 10, 11]; this points to imbalanced microbial colonization as a
potential factor in NEC.
Niño et. al. reiterate and condense much of the previously listed information, as well as identify
some important considerations, developments, and promising biomarkers for NEC [2].
Comparing the preterm and full-term infant gut environments, they state that toll-like receptor-4
(TLR4), a surface protein expressed more strongly in the premature gut and activated by
gram-negative bacteria, increases intestinal epithelial cell apoptosis, impairs mucosal healing,
and upregulates the release of proinflammatory cytokines [2]. It is proposed that gram-negative
bacteria, in activating this receptor, keep the expression levels of TLR4 high and contribute to
8

the onset of NEC [2]. This could in part explain why premature infants are more susceptible than
full-term infants [2]. Reviewing potential biomarker candidates, this paper lists those found in
blood (acute-phase reactants like C-reactive protein and proinflammatory cytokines like
TNF-alpha, interleukin-6, and interleukin-8) and in urine (intestinal fatty acid-binding protein,
liver fatty acid-binding protein, fecal calprotectin, trefoil factor 3, and claudin-3) [2]. Dr.
Sylvester and others have been exploring urine biomarkers [2, 13].
1.3 Critique of Current Technologies and Literature
Though predictive models may supplement traditional clinical diagnostics, many of the current
technologies do not provide a proven or adequate solution for NEC diagnosis [2, 9]. It follows
that research should turn to less explored lines of scientific inquiry to further supplement or even
replace what already exists.
The microbial milieu is increasingly considered to play a pivotal role in human health and
biology [38]. Current literature documents gut dysbiosis, or microbial imbalance in the gut, as a
likely contributor to NEC [2, 10, 11]. Gram-negative bacteria have been identified as possible
contributors to vulnerability to injury by conditions such as oxidative stress [2, 5]. However, a
more comprehensive understanding of the specific ways in which microbes contribute to NEC
has yet to be developed. Our analysis of the literature reveals that many of the biomarkers listed
as most promising are factors released due to cell injury and inflammation, and are perhaps
approaching the issue from too narrow a viewpoint. We respectfully argue that while these
factors should still be explored, not enough bacteria-related metabolites and factors have been
investigated thus far. Discovery may result from researching such factors, like butyrate and other
fermentation products of bacteria [12], which have been implicated in several past and recent
publications [5, 10, 11]. The Sylvester Lab’s recent published data (see section 3.9 for a
description) appears to be one of the first to explore butyrate in significant depth [5], but butyrate
is not the only product related to bacteria. We propose widening and deepening the search area
overall.
Moreover, we hold that more emphasis should be placed on strategically choosing the best
source of biomarkers with future applications in mind. Blood, urine, and stool are three possible
sources for NEC biomarkers. Because premature infants are so small, blood is limited in volume
and difficult and invasive to sample. Parents are also hesitant to consent to sampling. Therefore,
blood is perhaps not the ideal biomarker source for development into the kind of quick and easy
bedside diagnostic test that would best facilitate diagnosis, despite the promise shown for blood
biomarkers like C-reactive protein and inflammatory cytokines [2]. The Sylvester Lab’s work
with urine biomarkers has proven successful, but because the diagnostic strategies are not fully
validated yet, there is still a need to continue searching [2]. Fecal biomarkers come directly from
9

the disease environment. Collecting stool for screening would be simple, noninvasive, painless,
and sustainable, and would allow us to study any bacterial fermentation products of interest. It
offers more opportunity for pure discovery, and is useful from a humanitarian and engineering
perspective.
Finally, while many of the biomarkers listed are more correlative, researchers may benefit from
choosing to explore biomarker candidates that suggest a stronger causative relationship with
NEC. This will accomplish two tasks simultaneously: finding a useful biomarker while also
uncovering more about NEC’s mysterious etiology.
Current invasive methods and broad-spectrum antibiotic treatments might contribute to gut
dysbiosis [11], doing more harm than good. Strategies targeting the gut microbiome and/or
microenvironment in a less destructive and invasive way, such as pre and probiotics or
damaging-molecule inhibitors [5, 7], may be a better approach; however, without etiological
knowledge, developing new treatments becomes guesswork. By identifying and exploring factors
of interest with causation in mind now, we can better formulate treatment strategies later on.
1.4 Project Goal
Herein we address the pressing concerns that (1) the rate limiting step for reducing
disease-onset-to-treatment time is diagnosis, but the nonspecificity of current diagnostic methods
impedes early and accurate diagnosis; (2) that there are no known specific and useful fecal
biomarkers to aid physicians in diagnosis; and (3) that despite decades of research on the disease,
much about NEC’s etiology remains unknown. To address these concerns, we aim to identify a
useful fecal biomarker and help illuminate its related molecular mechanisms through preliminary
research studies.
We began by plating HIEC-6 and HT-29 cells with various factors, chosen to represent an array
of biomarker sources and potential disease-associated phenomena. After narrowing down
specific factors of interest based on morphological and other notable changes they induce, as
well as verifying that HT-29 is an acceptable choice for our study, we plated these two factors
(both detectable in stool) with HT-29 cells. After choosing one factor of interest as our main
focus, we plated it over varying HT-29-cell confluency to confirm that the observed phenomena
are related to cellular mechanisms, collected more detailed results, and ultimately performed a
more detailed analysis of these results. This proof-of-concept study will pave the way for
higher-level research on our factor of interest in the future.
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1.5 Backup Plan
The primary point of vulnerability in our design is identifying a factor that warrants more
detailed study. Should we fail to identify a factor using the proposed method, we may need to
screen a larger array of factors for evidence of disease phenomena. Another potential failure
could be that HT-29 does not make a suitable substitute for HIEC-6 in the context of our study.
Should we encounter this obstacle, we can look into using another human adenocarcinoma cell
line isolated from epithelial intestinal tissues such as Caco-2 or HuTu-80 [15, 16]. However, it
may be that in general a cancer cell line, perhaps due to fundamental metabolic differences or
other factors, is not the proper cell model for our purpose; if so, we can use HIEC-6 cells despite
their disadvantages for an early-stage study.
1.6 Significance
Our project has several significant implications. If successful, it may vastly benefit physicians,
NEC patients and their families, and the field of medicine.
NEC risk is inversely correlated with gestation time [2]. Current neonatal healthcare techniques
and technology have contributed to the incidence of NEC in the way that they have allowed for
the survival of infants outside the womb at increasingly early gestation times [2, 6, 17]. Neonatal
healthcare for premature infants will likely continue to improve, meaning that it will enable
viability of infants with increasing susceptibility to NEC [2, 17]. As such, NEC will only become
more prevalent despite the consistent percentage of premature births it affects. Given the
weaknesses in current diagnostic methods and the plateau of NEC survival rate [2], a growing
prevalence of NEC will mean that more and more premature infants will die of this disease.
Therefore, there is a pressing need to improve early and accurate diagnosis, as well as understand
the underlying mechanisms of the disease so that researchers can develop new measures to fight
it. The biomarker screening process may contribute to present understanding of NEC’s molecular
underpinnings, which will ultimately inform the development of new treatments [2].
Through a point-of-care diagnostic test (one that can be performed onsite or at the bedside), an
easily accessible and reliable biomarker would facilitate accurate, early diagnosis, decreasing the
time between disease onset and treatment and perhaps increasing NEC survival rate. Compared
to other methods, sampling stool for biomarker testing is noninvasive, non-harmful, and
potentially more fruitful. Thus, finding a fecal biomarker would presumably enable a superior
method for NEC diagnosis.
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1.7 Team and Management
1.7.1 Team Members
Table 1. Project Members

Member

Degree

Email

Daniela Campa

Bioengineering Biomolecular Track

dcampa@scu.edu

Kyle Sullivan

Bioengineering Biomolecular Track

k3sullivan@scu.edu

Advisor

School

Email

Dr. Jonathan Zhang

Santa Clara University

zzhang@scu.edu

Dr. Guo-Zhong Tao

Stanford University

gtao@stanford.edu

Table 2. Project Advisors

1.7.2 Project Budget
SCU Engineering generously granted us $1000 for our project. Materials for our work in the
Stanford lab were graciously provided by Stanford. Since we did not have time to perform
planned experiments at SCU, we used our grant to restock vital materials in SCU’s lab as
summarized in Table 3 below.
1.7.3 Project Timeline
During fall quarter, our team traveled to a satellite lab of Stanford University to tour and
interview for acceptance. Over the course of the weeks following our acceptance, Stanford
University and Santa Clara University discussed the specifics and liabilities associated with
collaboration. During this time, we began conducting our literature search on relevant subjects,
which we continued for the duration of the project. Our team was officially approved week 10 of
fall quarter. We spent winter break going through necessary lab safety and HIPAA training
before starting our lab work. Once in the lab, we conducted routine experiments with the
Stanford research team throughout winter and spring quarters. After familiarizing ourselves with
the research team, lab layout, relevant subjects, and experiment protocols, we had the privilege
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of contributing original experimental design to the project. We presented our work at the Senior
Design Conference on May 9, and compiled the information into our thesis. A Gantt chart
summarizing our project timeline can be found in Appendix A.
Table 3. Materials Ordered and Total Costs

Product Name

Quantity

Price ($)

Clear 1.5mL Cuvettes (500 count)

3

259.41

Blue 1.5mL Cuvettes (100 count)

3

116.64

Qproteome Mammalian Protein Prep Kit

1

227.00

LB Broth (1L)

1

41.15

Agar Medium (1kg)

1

273.41

Total:

917.61
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Chapter 2: Plating HIEC-6 and HT-29 Cells with Various Factors
2.1 Introduction
The cell lines we used for this experiment are human intestinal epithelial cells (HIEC-6) and
human colorectal adenocarcinoma cells (HT-29). HIEC-6 cells are isolated from the fetal small
intestine [18] and have a doubling time of approximately 96 hours. HT-29 cells, isolated from
cancerous colon epithelium [19], are hardier than HIEC-6 and have a doubling time of about 48
hours. Both of these cell lines are adherent [19, 20], meaning that if they are healthy they will
appear flat and spread out on the plate under the microscope; if they are round and/or detached,
they are either already dead or will die shortly.
We used several different factors to treat the cells in this experiment, including: (1) TNF-alpha, a
proinflammatory protein and potential biomarker [2, 21]; (2) lipopolysaccharide (LPS), an
endotoxin on the membrane surface of gram-negative bacteria [22]; (3) hydrogen peroxide
(H2O2), a strong oxidizer to induce oxidative stress [23, 24]; (4) butyrate, the anion of the
short-chain fatty acid called butyric acid and a known fermentation product of certain kinds of
bacteria [12]; and (5) Candidate-X, an undisclosed, soluble fermentation product of bacteria. The
plated cells were visualized under an optical microscope to analyze morphology changes over
time as a result of treatment. Please refer to Appendix B for a more detailed background on the
first four factors listed.
2.2 Key Constraints
Our project involves in vitro cell culture models for preliminary research. Since many of the key
constraints for this project remain relatively the same throughout, this section summarizes the
common key constraints in addition to the ones that are specific to this chapter.
In cell culture experiments, sterile technique must be maintained or else contamination will kill
the cells and ruin the results. Cell lines chosen must be biologically relevant to the in vivo target
environment. More generally, key constraints of preliminary studies are influenced by the end
goal: reaching the later-stage research phase. Specifically in terms of time, the goal is to speed up
the timeline of preliminary studies to reach the later stages as soon as possible. In terms of cost,
the goal is to save money for the more focused later-stage studies. The best experimental design
for us is one that balances biological relevance with time and cost efficiency.
We are currently unable to obtain samples directly from the intestinal microenvironment to
establish basal levels of various factors in healthy infants and test for abnormal concentrations in
NEC infants, so concentrations obtained from infant stool in combination with in vitro o r animal
14

models are our main options. For disease modeling, in vitro studies are often conducted first as
proof of concept. For in vitro models in early proof-of-concept studies, one can sacrifice certain
elements of experimental design--such as fidelity of in-vitro-t o-in-vivo comparability--in favor of
speed and cost, as long as one can demonstrate the experimental design is still valid.
Ideally, for NEC disease studies we would choose a cell line that closely mimics the in vivo
target environment: the premature gut. While HIEC-6 cells are isolated from the fetal small
intestine [25], and are therefore the better cell line for mimicking our target environment, their
doubling time of approximately 96 hours renders them inefficient to culture. In contrast, HT-29
cells are hardy and have a doubling time of about 48 hours, so they are easier, somewhat cheaper
[25, 26], and faster to culture. HT-29 also have a lineage somewhat similar to the target
environment, being isolated from colon cancer [19]. Considering all factors of experimental
design for our project, HT-29 would be the better choice if we can prove biological relevance.
However, if the results of our project are promising, we will transition from using HT-29 to
HIEC-6 in the future.
In our project, we use visualization of cell morphology in favor of more detailed but more
expensive methods. The Sylvester Lab does not have certain machines for more detailed
analysis; when needed, the research team sends samples to an offsite lab and pays for content
analysis. SCU has liquid-chromatography-mass-spectrometry (LC-MS) onsite, but each use costs
money and transporting biological samples and materials back and forth between schools is
neither quick nor simple. This kind of detailed analysis will be reserved for future work, after we
can prove our factor of interest is worth exploring.
A key constraint limited to this chapter is that HIEC-6 and HT-29 are different cell lines, and
therefore require somewhat different culture methods. For example, HIEC-6 is more sensitive, so
we must use weaker trypsin; in contrast, HT-29 is hardier, so we can use stronger trypsin. We
must be careful not to confuse these so as to not damage cells before treatment with factors.
2.3 Design Approach
Stanford provided the experimental design for this chapter. In this experiment, we explored
biomarkers from the literature as well as the propositions we outlined in our critiques. By testing
a wide array of factors, we were able to take a more comprehensive look at possible biomarkers
and disease mechanisms. We cultured well-studied cell lines--one that is known to be
biologically relevant and one this experiment sought to prove is biologically relevant--in well
plates, and treated them with various factors. Cellular damage was assessed by examining cell
death and morphology changes. By testing these cell lines in parallel, we narrowed down factors
of interest while at the same time assessing the biological relevance of the cancer cell line for the
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next experimental steps. We repeated the experiment at least three times to ensure our results
were reproducible.
2.4 Supporting Analyses
The design successfully accomplished our objective for this experiment. We confirmed that
HT-29 was biologically relevant for our next steps, as the results for both cell lines were similar.
In addition, the lack of cell damage ruled out TNF-alpha, LPS, and H2O2 as likely causative
agents in NEC, while the presence of cell damage allowed us to select butyrate and Candidate-X
as factors of interest.
2.5 Expected Results
To reliably assess biological relevance of HT-29, we need to keep each treatment as consistent as
possible across trials and cell lines; variations in treatment could influence our results and make
it difficult to compare the two cell lines. We expect to see relatively consistent results for each
cell line respectively. If we see different results across trials for a cell line, it is likely that the
conditions for each treatment were not kept consistent. In addition, we must maintain sterile
technique at all times during cell culture; failure to do so would force us to redo the trial and thus
delay our progress. If we maintain sterile technique, we should see cells with morphology, size,
and doubling time consistent with the proper cell types. Since a very small percentage of cells
typically die regardless of the conditions, controls should show a small but negligible amount of
cell death at time of visualization.
2.6 Backup Plan
During this process, it is possible that we will fail to identify a factor that warrants more detailed
study. If this happens, we will screen a wider array of factors for evidence of disease phenomena.
Based on our literature search and critiques, we would consider testing other
inflammation-related factors listed, but primarily look into exploring other gut-bacteria-related
metabolites like acetic acid [10]. While this is not a well-established protocol, our project
involves discovery and so our lines of scientific inquiry are guided not by established methods,
but by cutting-edge research and possible missed opportunities.
In addition, this experiment may show that HT-29 does not make a suitable substitute for
HIEC-6 in the context of our study. Should we encounter this obstacle, we can look into using
another human adenocarcinoma cell line isolated from epithelial intestinal tissues such as Caco-2
(isolated from the colon) or HuTu-80 (isolated from the duodenum), which are both well studied
and widely used for similar applications [14, 15, 27]; and repeat this experiment with the new
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cell line. ATCC recommends similar culture methods and materials for these cell lines compared
to HT-29, so the transition would be relatively simple [11, 16]. However, it may be that in
general a cancer cell line, perhaps due to fundamental metabolic differences or other factors, is
not the proper cell model for our purpose; if so, we can use HIEC-6 cells for the next steps
despite their disadvantages for an early-stage study.
2.7 Materials and Methods
Growth medium preparation, cell culture, and cryopreservation for each cell line were generally
conducted according to ATCC’s guidelines [25, 26], but we have included below our own more
detailed version of the protocol and materials needed for cell splitting and changing media.
For ATCC’s protocol on culture methods (including preparation of complete growth medium,
subculture methods, cryopreservation, and culture conditions) for each cell line, please visit the
following websites:
HIEC-6 [25]:
https://www.atcc.org/en/Products/Cells_and_Microorganisms/By_Tissue/Intestine
_Small/CRL-3266.aspx#culturemethod
HT-29 [26]:
https://atcc.org/Products/All/HTB-38.aspx#culturemethod
2.7.1 Cell Culture Materials
General Materials
● EDTA
● Phosphate Buffered Saline (PBS) pH 7.4 (1X) - (Gibco® by Life Technologies, Ref. No.
10010-031)
● 70% Ethanol solution
● IncuSafe CO2 incubator, setpoint 37ºC, 5% CO2 - (Panasonic Healthcare Co., Ltd;
Model No. MCO-18ACL-PA)
● Leica DMIL microscope - (Leica Microsystems, Model No. 090-135.001)
● Sorvall ST 8R Centrifuge - (Thermo Scientific)
● SterilGARD laminar flow hood - (The Baker Company, Model No. SG 404-M)
● Fisherbrand® SureOne micropipette tips, various sizes
● Micropipettes, various sizes
● Falcon® serological pipette tips, various sizes
● Easypet 3 serological pipette gun - (Eppendorf)
● Falcon® centrifuge tubes, various sizes
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● 9” Disposable Pasteur Pipettes, borosilicate glass / non-sterile - (Fisherbrand®, Catalog
No. 13-678-20D)
● Costar® 10 mm, 24- and 6-well plates; tissue-culture treated / sterile - (Corning
Incorporated)
● -153ºC liquid nitrogen storage tank - (Thermo Fisher Scientific, Model No. 7400)
● -20ºC refrigerator - (Kenmore)
● 4ºC refrigerator - (Kenmore Elite)
HIEC-6 Culture Materials
● Complete Growth Medium (4% FBS)
○ OptiMEM 1 Reduced Serum Medium - (Gibco® by Life Technologies, Catalog
No. 31985)
○ Fetal Bovine Serum (FBS) - (ATCC®, Catalog No. 30-2020)
○ 20 mM HEPES
○ 10 mM GlutaMAX (Gibco® by Life Technologies, Catalog No. 35050)
○ 10 ng/mL Epidermal Growth Factor (EGF)
● HIEC-6 cells, frozen (ATCC®, CRL-3266™)
● 0.25% Trypsin-EDTA (1X) - (VWR Life Science, Catalog No. 02-0154-0100)
● Freeze medium (95% growth medium, 5% DMSO)
○ Complete Growth Medium (4% FBS)
○ Dimethylsulfoxide (DMSO) - (ATCC® 4-X™)
HT-29 Culture Materials
● Complete Growth Medium (10% FBS)
○ McCoy’s 5a Medium Modified - (ATCC®, Catalog No. 30-2007)
○ Fetal Bovine Serum (FBS) - (ATCC®, Catalog No. 30-2020)
● HT-29 cells, frozen (ATCC® HTB-38™)
● TrypLE™ Express, [+] Phenol Red - (Gibco® by Life Technologies, Ref. No.
12605-010)
● Freeze medium (95% growth medium, 5% DMSO)
○ Complete Growth Medium (10% FBS)
○ Dimethylsulfoxide (DMSO)
2.7.2 Cell Culture Methods
Splitting Cells
1. Ensure all cell culture surfaces and tools have been sterilized with 70% Ethanol.
2. Retrieve cell culture plate with cells from 37℃ incubator.
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3. Visualize cells under bright-field microscope to ensure they are at the desired confluency
(70-90%).
4. Place cell culture plate in laminar flow hood and suction out the old media.
5. Add 1X PBS to the plate in accordance to the plate size.
a. 10 mm plate receives 3 mL of 1X PBS.
b. 6-well plate receives 1 mL of 1X PBS.
c. 24-well plate receives 500 µL of 1X PBS.
6. Tilt the plate back and forth to evenly mix the 1X PBS and then suction up the PBS.
7. Add Trypsin (see materials for proper type for desired cell line) to the plate and place
back in the 37℃ incubator for 3 to 5 minutes.
8. Hold the plate up to the ambient light to visualize the bottom of the plate for cell
detachment, and visualize plate under bright-field microscope to confirm.
9. Add required amount of media (see materials for proper type for desired cell line) to each
plate while tilting it, and cycle the media from top to bottom in order to ensure maximum
collection of viable cells.
a. 10 mm plate receives 3 mL of media.
b. 6-well plate receives 1 mL of media.
c. 24-well plate receives 500 µL of media.
10. Add the cell mixture to a 15 mL centrifuge tube and centrifuge at 200g to 300g for 3
minutes.
11. Suction out the supernatant, taking care not to suction out the pellet. Tilt the tube to make
the liquid easier to suction.
12. Resuspend the cell pellet with media to the desired concentration, and add to a new,
sterile plate. Make sure the plate is labeled with your name, date, and cell line.
13. Place the plate back into the incubator.
Changing Media
1. Ensure all cell culture surfaces and tools have been sterilized with 70% Ethanol.
2. Visualize cells under bright-field microscope to ensure they are at the desired confluency
(< 70%).
3. Place cell culture plate in laminar flow hood and suction out the old media.
4. Add 1X PBS to the plate in accordance to the plate size.
a. 10 mm plate receives 3 mL of 1X PBS.
b. 6-well plate receives 1 mL of 1X PBS.
c. 24-well plate receives 500 µL of 1X PBS.
5. Tilt the plate back and forth to evenly mix the 1X PBS and then suction up the PBS.
6. Add the desired amount of media (see materials for proper type for desired cell line) to
the plate, which now contains only viable cells.
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2.7.3 Materials for Treatment with Various Factors
●
●
●
●
●

Fisherbrand® SureOne micropipette tips, various sizes
Micropipettes, various sizes
Falcon® serological pipette tips, various sizes
Easypet 3 serological pipette gun - (Eppendorf)
Phosphate Buffered Saline (PBS) pH 7.4 (1X) - (Gibco® by Life Technologies, Ref. No.
10010-031)
● Deionized Water from MilliQ system
● Fisherbrand™ Premium Microcentrifuge Tubes: 1.5 mL
● Factors obtained from Sigma-Aldrich
○ TNF-alpha
○ lipopolysaccharide (LPS)
○ hydrogen peroxide (H2O2)
○ Butyrate (acid form)
○ Candidate-X (acid form)
2.7.4 Methods for Treatment with Various Factors
1. Calculate the desired concentration for each factor.
2. Identify required suspension media.
a. Most likely Deionized Water, PBS, or cell culture media for applicable cell type.
3. Weigh out desired amount of factor.
4. Add individual factors to their own 1.5mL Microcentrifuge tube.
5. Suspend factors with suspension media.
6. Calculate the volume of suspended factor must be added to cell culture wells to obtain
desired final concentration.
7. Add calculated volume to the wells if the cells have had time to adhere to the bottom of
the well.
8. Once factors are added, tilt the cell culture plate back and forth to homogenize the
solution.
9. Visualize cells with a brightfield microscope at desired time points.
10. Repeat steps 1-9 at least three times in separate trials.
2.8 Results
Results were similar for all trials all trials. TNF-alpha, H2O2, and LPS had minimal to no notable
effect on cells relative to the control. By visualizing the plate under the microscope, we
determined that butyric acid induced a moderate amount of cell death while Candidate-X in acid
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form induced widespread cell death. Both induced notably more cell death than the control.
Morphology changes for butyric acid include a transition from flat to round followed by
detachment, death, and lysis. Morphology changes for Candidate-X include freezing in place
(remained flat with no rounding), death, and eventual detachment with no lysis. There were also
unidentified granules in the cytoplasm. We observed that the effects of Candidate-X took longer
to manifest compared to butyric acid. While the onset time of effects was delayed for HIEC-6
compared to HT-29, we observed the same phenomena for both cell lines.
We noted a significant color change from pink to yellow in the Candidate-X treated well. An
image of this can be found in Chapter 3, Figure 1.
2.9 Discussion
Our results are most likely reliable due to their reproducibility. HIEC-6 cells took longer than
HT-29 cells to reveal the changes, which may be related to the elevated metabolic demands of
HT-29 as a cancer cell line. However, given that we observed the same ultimate effects across
cell lines, we are able to confirm the biological relevance of HT-29 for use in our next steps. This
will speed up the timeline of our project.
The lack of notable effects of the first three factors suggests that there is not a strong causative
relationship between them and NEC; rather, in the context of the literature and known
physiology, it is more likely these are correlative and not the ideal line of inquiry for our
purpose.
Given the occurrence of cell lysis, the morphology of butyric-acid-induced cell death is
consistent with necroptosis or necrosis [18, 28]. The morphology of Candidate-X-induced cell
death appears distinctly different from that of the most familiar pathways [18]. These two factors
are more likely to have a causative relationship with NEC due to their apparently cytotoxic
effects. Therefore, we have singled these out as our factors of interest for our next steps.
Perhaps the most surprising result of all was the significant color change with Candidate-X. The
growth media contains phenol red, a colorimetric pH indicator [29]. At neutral pH, the
supernatant appears pink, as seen in control wells (refer to Figure 1 in section 3.8), but the
yellow color indicates an acidic (i.e. low) pH. Since the color is consistently still pink
immediately following the treatment, we know that the pH change is something that occurs over
time. Given the pH change, widespread cell death, and puzzling morphology, we hypothesize
that Candidate-X may end up being an exciting line of inquiry for this project and perhaps have
implications for understanding why NEC’s pathophysiology is so devastating.
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Chapter 3: Plating HT-29 Cells with Factors of Interest
3.1 Introduction
Candidate-X and butyrate are fermentation products of bacteria [12]. In gut dysbiosis, it is
possible that the normal levels of these factors may be increased beyond what the preterm
intestine can handle, reaching cytotoxic levels. Prior to conducting this experiment, the research
team identified threshold concentrations inducing cell death for both factors of interest; this is
significant because it allows us to compare the in vitro model to levels found in stool, and better
mimic the stressors experienced in the in vivo e nvironment. This will be explained further in
section 3.3.
In this experiment, we use these threshold concentrations to guide our treatment of cells in well
plates and study cell morphology changes over time.
3.2 Key Constraints
As touched on in section 2.2, a key constraint is that it is not currently possible to sample directly
from the affected in vivo microenvironment for concentrations of factors of interest. With diluted
concentrations of factors of interest obtained from stool, we must determine through trial and
error what concentrations may be in the intestinal microenvironment and test this in vitro. The
experimentally determined threshold concentration of Candidate-X, not the concentration found
in NEC stool prior to treatment, should be the primary concentration for treating the cells. For
additional key constraints, please see section 2.2.
3.3 Design Approach
Stanford provided the experimental design for this chapter. Plating different neutral-pH forms of
the factors will determine if the factors’ acidity is responsible for the effects we observed. The
research team had recently identified (via trial-and-error treatments in 96-well plates with
varying factor concentrations) that butyrate induced cell death at a threshold concentration of 10
mM, while Candidate-X induced cell death at a threshold concentration of 50 mM. With this
knowledge, we performed an experiment that tested the reproducibility of previous results in
tandem with a more detailed morphologic analysis.
3.4 Supporting Analyses
This experiment confirmed that effects were reproducible for the two factors of interest in all
forms, evidenced by the occurrence of similar cell death levels and color changes. The more
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detailed recordkeeping and testing also gave more in-depth information on the timeline of effects
and morphology. Similar results across different forms of each factor confirmed that their acidity
/ the initial extracellular pH were not factors in these effects.
3.5 Expected Results
To complete this experiment, we need to successfully culture and treat the cells with a known
concentration of factors, maintaining sterile technique at all times. Should we successfully set up
our well plate, we expect to see wells with cells and pink supernatant at time of treatment.
Controls should show a small but negligible amount of cell death at time of visualization. Total
cell death will be estimated again through visualization under the microscope after at least a day,
and this time confirmed and quantified using Keratin-8 (K-8, or cytokeratin[CK]-8) assays.
3.6 Backup Plan
HT-29 may not be biologically relevant; this will have been established in the previous
experiment, and an alternate cell line will have been validated and chosen for this experiment.
Should we encounter this obstacle, we will adapt our protocol to match the chosen cell line
according to ATCC’s guidelines and order any additional materials as needed.
3.7 Materials and Methods
This section includes a list of materials and new protocols used for treatment of HT-29 with
butyrate and Candidate-X. For HT-29 culture materials and methods, please refer to sections
2.7.1 and 2.7.2.
3.7.1 Materials
Required cell culture and plating factor material is the same as Section 2.7.1, with the exception
of the following:
● 6-well plates only
● Factors obtained from Sigma-Aldrich (acid neutralization step performed in Stanford lab)
○ Butyrate (acid and neutralized acid with NaOH)
○ Candidate-X (acid, neutralized acid with NaOH, and neutral sodium salt)
● Sodium hydroxide solution (NaOH)

23

3.7.2 Methods for Treatment with Factors of Interest
The method for HT-29 cell culturing and plating Candidate-X is the same as Section 2.7.2, with
the exception of neutralizing the acid forms with NaOH solution to the desired physiological pH.
Cell death percentages are 100 times the amount of cell death in the plate divided by the total
amount of cells, dead or alive. The research team used K-8 assays for more precise quantification
of total cell death for comparison to baseline cell death seen in the controls; we should note that
this step was performed mostly by other lab members and was not a significant part of our work
in the lab, but Appendix C1 includes the K-8 assay protocol used. Further information may be
obtained by consulting the Sylvester Lab.
3.8 Results
Results were consistent across trials. The research team determined that butyrate induced about 5
to 10% cell death while Candidate-X induced about 90 to 100% cell death compared to
compared to the controls.
Again, morphology changes for butyric acid include a transition from flat to round followed by
detachment, death, and lysis into small parts. We were able to determine that the onset time of
these effects are within 24 hours in HT-29. Morphology changes for Candidate-X include
granules in the cytoplasm, freezing in place while still flat and fully intact, and over time, almost
all the cells lifting off the plate. We were able to determine that the onset time was between 48 to
72 hours in HT-29. For both factors, the same effects occurred regardless of initial pH; that is to
say, (1) the acid and neutralized acid forms of butyrate all produced the same outcome, and (2)
the acid, neutralized acid, and neutral sodium salt forms of Candidate-X all produced the same
outcome.
As before, we noted a distinct color change from pink to yellow in the Candidate-X-treated well.
The control also shows a very slight color change. These results are shown below in Figure 1.
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Figure 1. Wells treated with Candidate-X and butyrate as neutralized acids. A 6-well plate was used to
compare effects of neutralized acid forms of Candidate-X (50 mM; boxed in red) and butyrate (BA) (50, 10 mM;
boxed in blue) on HT-29 cells to the control (boxed in black). The other wells were used at the same time for a
different project, and are not relevant to this experiment. No picture for the acid forms or neutral salt form is
available.

3.9 Discussion
Quantifications of cell death percentages coincide with our visual estimates in Chapter 2.
Butyrate’s effects on cells were the same for acid and neutralized acid forms, so they are not due
to its acidity / the initial extracellular pH. As seen in Chapter 2, we observed a distinct color
change in the Candidate-X-treated well; this further demonstrates the reproducibility of the pH
change (see Figure 1). The fact that the neutralized acid and neutral salt forms of Candidate-X
produced the same effects as the acid form shows that the morphology changes, cell death, and
pH change over time are unrelated to its acidity / the initial pH. We hypothesize this is a
cell-related phenomenon: that Candidate-X treatment might induce some kind of metabolic
change in which the cell produces increased amounts of hydrogen ions and/or becomes impaired
at regulating extracellular pH. We will begin testing this hypothesis in the next chapter. An issue
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to note, however, is that the control does show a very slight color change; while the change is
negligible, it suggests that the cells can produce small levels of an acidic substance on their own.
The morphology of Candidate-X-induced cell death does not fit apoptosis, necrosis, or
necroptosis, as there were granules in the cytoplasm and no apoptotic bodies or cell swelling,
shrinkage, or autolysis [18]. Because of the unique morphology along with the difference in
onset time of effects compared to butyrate, we believe that cells treated with Candidate-X
undergo a different cell death pathway than what we have observed with cells under other
treatment conditions. In addition, our results point again to causation for NEC. As a result, we
have decided to continue to the next step with Candidate-X as our primary factor of interest.
Butyrate’s cell death pathway was ultimately proven to be necroptosis in a separate publication
by the Stanford research team; this represents a huge and exciting leap forward in understanding
the molecular mechanisms at work in NEC, and will likely lead to NEC-specific treatments [5].
A small molecule inhibitor has already shown promise in this regard [5]. Our work with
Candidate-X may have similar success in the future.

26

Chapter 4: Plating Candidate-X with Varying Cell Confluency of HT-29
4.1 Introduction
Candidate-X is our primary factor of interest. Recent, unpublished data from UC Davis show that
Candidate-X concentration in confirmed-NEC infant stool prior to standard-of-care treatment,
sampled onsite at Stanford’s hospital, is four to ten times the basal concentration as determined
by analysis of healthy infant stool samples. The concentration decreases to basal levels following
treatment for NEC. These results prove that an elevated concentration of Candidate-X in stool is
strongly correlated with the disease.
Because the UC Davis results are unpublished, we are currently unable to include a citation for
them. In the interest of protecting intellectual property we are also unable to provide more
detailed background information on Candidate-X other than what has already been said, as this
may reveal its identity.
We already know from the previous experiments that Candidate-X induces up to 100% cell death
with unique morphology in vitro. T
 his experiment aims to verify or disprove that the pH change
we observed is correlated with cell interactions with either Candidate-X or any related
intermediates in solution.
4.2 Key Constraints
As explained in section 2.2, ideally we would choose HIEC-6 to mimic the premature gut
environment when studying NEC. However, in section 2.8 we outlined that the same supernatant
color change, cell morphology, and widespread cell death for both HIEC-6 and HT-29 was
already observed following Candidate-X treatment; the only observable difference across cell
lines was the onset time of the effects, suggesting that HT-29 is an adequate substitute for
HIEC-6 in the context of Candidate-X treatment. Since the literature we reviewed has yet to
document Candidate-X as a major factor of interest in NEC, we can consider this experiment to
be in the very early stages; the research does not yet require as stringent of a match to the in vivo
environment. Also, due to time constraints, we were unable to conduct multiple trials. Therefore,
we are unable to assess the reproducibility of our results. Please see section 2.2 for further detail
and additional key constraints.
4.3 Design Approach
We have had the privilege of designing and implementing our own experiment to determine if
the color change is related to the growth media or the cells.
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In this experiment, we adapted the chemical dilution protocol to set up wells with varying cell
confluency (i.e. concentration) in a uniform extracellular environment. Our design was inspired
by the fact that the previous experiments have a major weakness: they do not explore
Candidate-X treatment in wells with no cells, so there are no data to prove that the color change
we see is directly related to a combination of Candidate-X and cells. Observing this control is
imperative before taking any further steps in exploring Candidate-X as a potential contributor to
the development of NEC. Moreover, even if the effects are independent of media components,
previous work varied the concentration of Candidate-X to determine threshold cell death
concentration but failed to assess how a constant starting extracellular environment affects cells
at varying confluency. An analysis of the correlation between the cells and Candidate-X’s effects
by varying the confluency will allow us to identify the direction in addition to the magnitude of
the effects. This is vital to understanding what molecular mechanisms may be at work following
the treatment.
4.4 Supporting Analyses
This experiment successfully ruled out media interactions and proved that Candidate-X’s effects
were cell-correlated, as varying cell confluency did produce a notable pattern in
Candidate-X-treated wells.
4.5 Expected Results
To complete this experiment, we need to establish a method of creating different concentrations
of cells to vary cell confluency and treat the cells with a constant concentration of Candidate-X
while maintaining sterile technique at all times. Should we successfully set up our well plate, we
should see no cells in the first column at any point. At time of visualization, we expect to see a
color change in the cells + treatment wells and negligible color change in the cells-only wells; if
not, the results would be inconsistent with our previous experiments and would indicate we may
have made a mistake. We should note that while the results can confirm correlation of
Candidate-X’s effects with cells, the experiment does not give enough detail to distinguish
between Candidate-X directly interacting with cells and Candidate-X creating an intermediate(s)
that interacts with cells. We can only hypothesize what is happening mechanistically based on
our knowledge of the molecule, which we are unable to fully disclose in this paper.
4.6 Backup Plan
As explained in preceding sections, HT-29 may not make a suitable substitute for HIEC-6 in the
context of our study. If HT-29 is not a suitable substitute, we will instead be using for this
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experiment whichever cell line has been validated and/or used in the previous experiments,
whether that is HIEC-6 or a human adenocarcinoma cell line other than HT-29.
In addition, this experiment may reveal that Candidate-X’s effects are related to the media.
Should we see color change with either well containing no cells, we will (1) look into different
media to test with Candidate-X for the same effects, choosing to use one in the future that shows
no effects; and (2) consider searching for or selecting another factor of interest for more detailed
exploration, as the Candidate-X’s effects may not be correlated with the cells, and therefore, not
necessarily involved in the disease mechanism.
4.7 Materials and Methods
This section includes a list of materials and new protocols used for treatment of HT-29 with
Candidate-X. For HT-29 culture materials and methods, please refer to Sections 2.7.1 and 2.7.2.
4.7.1 Materials
Required cell culture and plating factor material is the same as Section 2.7.1, with the exception
of the following:
● 24-well plates only
● Factors obtained from Sigma-Aldrich
○ Candidate-X (neutral sodium salt only)
4.7.2 Methods for Treatment with Candidate-X over Varying Cell Confluency
1. Estimate confluency of cells in bright-field microscope.
a. Should be approximately 90 to 100% if the cells are ready for passage.
2. Harvest cells in the same manner as the Cell Splitting protocol.
3. Calculate the percentage of cells needed from original plate to new well by dividing the
new wells surface area by the old wells surface area. Multiply value by desired
confluency percentage.
4. Pipette the calculated volume of resuspended cells concentration into the new well.
a. Set up in 8 wells of a 24-well plate with varying cell confluency (see Figure 2) as
2 rows of 4 wells
b. Row A: + NaX (wells treated with 50 mM NaX); Row B: - NaX (control wells
with no NaX)
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Figure 2. Schematic of experimental layout. Wells were set up with varying cell confluency across a row,
observed with (Row A) and without (Row B) NaX treatment. Column 1 contains no cells.

4.8 Results
Negligible color change was seen in the control wells (very slight color change ≥100% cell
confluency), and the X-treated well containing only media did not show any color change
whatsoever. The most intense color change was seen in the treated row, and intensity of yellow
color increased with cell confluency. These results are shown in Figure 3.

Figure 3. Before/after comparison of experiment in Fig. 2. Panel 1 shows the plate at time of treatment. Panel 2
shows the plate at time of visualization. Controls did not exhibit notable color change, but wells with cells + NaX
did. For these wells, amount of cell death and intensity of yellow color increased with cell confluency.

Morphology analysis again revealed granules in the cytoplasm, no apoptotic bodies, and no cell
shrinkage, swelling, or autolysis. Cell death occurred along approximately the same timeline as
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explained in section 3.8 and in the same amount, increasing with cell confluency just as the
intensity of color change increased.
4.9 Discussion
The morphology of Candidate-X-induced cell death again does not fit traditional apoptosis,
necrosis, or necroptosis. The lack of color change in the media-only control, the negligible color
change in the untreated controls, and the pattern of color change in the treated wells with cells
proves that the pH change was correlated with cell confluency and intensified with the addition
of Candidate-X. As previously mentioned in section 3.9, the effects of Candidate-X involve a
decrease in pH not due to the initial acidity of the treatment; the treatment triggers cytotoxicity
and a pH decrease that is in some way related to cell activity. With confirmation that the effects
correlate with cell activity, we can now begin considering potential avenues to explore in the
future.
The pH decrease following Candidate-X treatment could mirror acid exposure in vitro. While we
cannot cite sources to protect the identity of Candidate-X, poisoning with a precursor molecule is
known to induce metabolic acidosis in humans as the body processes the chemical into
Candidate-X, forcing the concentration of it beyond normal physiological levels. Granules we
saw in the cytoplasm may be explained by acidosis [30], though we do not have the expertise to
say this confidently. A study of the effects of acid on HT-29 for a disease called Barrett’s
esophagus states that:
“acid has a highly variable effect on cell proliferation and differentiation depending on
the pattern of acid exposure [....] Chronic acid exposure arrested cell proliferation,
whereas a 1 hour acid-pulse enhanced cell proliferation [....] Serum starvation attenuated
the hyperproliferative effect of an acid-pulse. In addition, the doubling time of at least the
first cell cycle after an acid-pulse was shortened. These results support a role for
extracellular pH on cell proliferation and differentiation of HT29 cells.” [31]
These findings indicate that the extracellular pH decrease we observed in our own experiment
may have influenced the cells’ metabolism and had an effect on their ability to thrive in the plate.
Since we ultimately observed the same effects as HT-29 in HIEC-6, a cell line that closely
resembles the premature intestine, we can say it is also possible that intestinal cells in NEC
infants experience similar effects. If premature intestinal cells are metabolically immature [5],
they may be much more vulnerable to damage and death upon experiencing acid-related
metabolic stress; more experiments need to be conducted before we can confidently assert this.
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Metabolic acidosis can be accompanied by increased lactic acid production [33], though a study
of the effects of bacterial fermentation products on the intestine of live infant mice concluded
that: “overproduction/accumulation of short chain fatty acids, but not lactic acid, in the proximal
colon and/or distal ileum may play a role in the pathogenesis of necrotizing enterocolitis in
premature infants” [10]. We originally hypothesized (based on the slight pH drop at ≥100%
confluency in the control) the damage might have something to do with lactic acid and
upregulation of the Warburg effect, a metabolic phenomenon wherein tumors and proliferative
tissues favor aerobic glycolysis and produce increased amounts of lactic acid [32]; the study’s
findings seem to suggest lactic acid is more of a bystander. However, the tests were performed in
vivo, Candidate-X was not one of the factors tested, and the noted cell death morphology
(inflammation and necrosis) does not match what we observed with Candidate-X. Therefore, it is
difficult to compare the findings of the study to our study of Candidate-X. Further experiments
will be needed to examine the extent of the Warburg effect’s involvement.
Overall, our project leaves more questions than answers. The final experiment and continued
literature search have given rise to our current hypothesis on Candidate-X: that beyond the
threshold concentration of 50 mM, Candidate-X treatment in vitro may mimic the effects of in
vivo poisoning with a Candidate-X precursor molecule, leading to metabolic acidosis and
ultimately cell death with autophagy (a result of cell starvation and a known outcome of acidosis
[34, 35, 36]). This could help explain why we see the effects much faster with the cancer cell line
than HIEC-6; cancer cells have a shorter doubling time and would likely experience serum
starvation more quickly. However, this hypothesis is largely built upon other hypotheses; many
layers must be rigorously experimentally explored before it is seriously considered. For example,
lactic acid concentrations must be determined and compared to see if there is a change in lactic
acid production following treatment with Candidate-X. We may also want to conduct
experiments to characterize any changes in expected doubling time. We have yet to conduct
more trials and repeat the experiment with HIEC-6. Even then, the in vitro environment we
would use neglects many of the dynamic aspects found in vivo, including an influx of nutrients.
On a fundamental level, we do not yet understand the complete mechanism behind the pH
decrease and cell death (i.e. what about Candidate-X triggers these effects, and if/how they are
interrelated).
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Chapter 5: Conclusion
5.1 Conclusion and Summary
This project aimed to identify a fecal biomarker for necrotizing enterocolitis (NEC). The disease
affects approximately 10% of preterm neonates, or infants with a gestation period of less than 37
weeks [1, 2, 4]. About one in four NEC cases results in death [5]. Currently, diagnosis is based
on nonspecific signs, some of which closely resemble sepsis and can lead to misdiagnosis [2, 6].
Our project identified several potential candidates for biomarkers, with focus on the main two
detectable in stool. After scrutinizing the candidates and conducting further experiments, the list
of candidates was narrowed down to only Candidate-X. Because of intellectual property
concerns, this team is unable to release the molecular name of Candidate-X.
Stanford obtained several stool samples from both healthy neonates and neonates with NEC.
After UC Davis ran quantitative analytical tests on stool samples, NEC neonates showed a
four-fold to ten-fold increase in biomarker concentration compared to healthy (control) infants,
suggesting that elevated Candidate-X concentrations in stool could be used as a parameter for the
diagnosis of NEC. The experiments we conducted in the Stanford lab build on these results, and
furthermore suggest that Candidate-X--given its cytotoxic effects--is involved in the causation of
NEC.
Additional verification of our findings is needed and will come through continued research on
the topic after this paper is released. Further reading on recent papers from the Sylvester Lab in
the Stanford School of Medicine is highly encouraged to have the most up-to-date and accurate
findings. So far, all experiments and research point to the validity of Candidate-X. This team was
preliminarily successful in identifying a fecal biomarker for NEC; however, further research is
needed to confirm specificity. Until then, we recommend that Candidate-X be used in
combination with current diagnostic methods and predictive models rather than as a standalone
diagnostic parameter.
5.2 Future Steps
We have identified many potential future steps for our project. The team has already begun the
first steps of mouse model studies. Besides this, we would also like to obtain more stool samples
and order assay kits for Candidate-X to (1) produce our own confirmation of the UC Davis
findings, and (2) increase the statistical power of Candidate-X’s correlation with NEC. This
would be a straightforward experiment, but it would require waiting for additional stool samples
to arrive. Because of the infrequency of collection and small amount of stool sampled from each
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infant, gathering enough samples may take several months. Further exploration into the
feasibility and timeline of this proposition is required.
Additionally, our experiments used HT-29 cells because of their faster doubling time and should
be reperformed with HIEC-6 cells in order to create the most representative in vitro model.
Because of the close proximity of the small intestine and colon, a co-culture with both cell types
may be a useful in vitro simulation of the native physiological environment. A non-cancerous
colon-derived cell line would be more biologically relevant than HT-29 and should be
considered as an alternative. However, this type of experiment could be hard to plan due to the
different requirements and characteristics of the cell types.
As the previous sections delineate, the colorimetric change in the media with the addition of
Candidate-X is clearly correlated with cells and not the media; however, further characterization
of the supernatant via LC-MS using SCU’s equipment will provide us with a better
understanding of Candidate-X’s cellular interactions. Conducting the testing at SCU will be
cheaper than sending it to other offsite labs. This experiment can involve repeating the Chapter 4
experiment with HIEC-6, and collecting the supernatant from each well in both rows (see well
plate layout in Figure 2) to create a graph of relative component concentrations over varying cell
confluency. We would also like to determine how pH values and lactic acid concentrations
change over time. The LC-MS data could give information on lactic acid content, and pH could
be measured via pH meter multiple times per day to determine the pattern of acid exposure. This
would help us explore the relevance of the Warburg effect and begin to illuminate the metabolic
phenomena at work. If we want to study changes in doubling time, we could try to develop a way
to compare the amount of cells in the controls to the amounts in the treated wells using cell
pellets that would otherwise be discarded after supernatant extraction. To more closely monitor
the culture environment and replicate the in vivo environment in vitro, a small perfusion
bioreactor could be used instead of culture in plates, but this might be prohibitively expensive
(especially since adherent cells would require special materials for culture in suspension).
The molecular underpinnings of Candidate-X in NEC remain unknown, as does the level of
specificity of elevated Candidate-X in NEC stool. More in-depth and intensive research was
outside the scope, funding, and time constraints of our project, but still serves as a crucial step in
validating Candidate-X as a specific biomarker and causative agent in NEC. Should the
biologically relevant interactions be characterized and the specificity further confirmed, an
appropriate diagnostic tool can be developed through utilizing homogeneous interactions. One
proposed method could be based on a colorimetric assay. If the difference in concentration of
Candidate-X between healthy and NEC infants is large enough, we may perhaps be able to
circumvent the need for expensive detection devices like microplate readers (likely unavailable
onsite in most clinical settings) and develop an assay protocol that only requires visual
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analysis/comparison. Creating a point-of-care diagnostic tool like this will provide physicians
with a method to deliver quick results with sufficient sensitivity and selectivity [37], thus
improving NEC patients’ prospects of survival and reallocating resources more efficiently in the
healthcare system.
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Chapter 6: Engineering Standards
6.1 Economical Concerns
Our project hopes to ultimately decrease the medical costs associated with diagnosing NEC.
Currently, physicians order an array of tests aiming to create a differential diagnosis that may be
a positive indicator for NEC, but cannot find a solution that is closer to binary; we hope to
decrease the number of tests ordered by developing a biomarker detection test that offers
physicians a more binary solution. Additionally, we want to be conscientious about the cost of
the materials required; we want to avoid extravagant and/or unnecessary spending.
6.2 Manufacturability Concerns
Creating a detection protocol (perhaps a homogenous-phase assay, in this case) for the proposed
soluble NEC biomarker is a long-term objective of our project. We hope our device is held to
high standards so as to avoid negatively affecting the user. We would need to design a device
with a reasonable shelf life so that physicians will not need to worry about needing to regularly
discard unused materials. We want to use material that undergoes the appropriate quality
assurance testing to ensure that (1) there are no issues associated with our final product and (2)
that it maintains its stated efficacy over the course of its shelf life.
6.3 Ethical Concerns
Having a specific biomarker to diagnose NEC will help improve the quality of life of the
stakeholders involved. The patient will benefit from more rapid and effective treatment, reducing
the duration and severity of pain/suffering and potentially reducing mortality. The physicians
will benefit from biomarker-assisted diagnosis because they will need to order fewer tests and be
able to allocate their time more effectively. The patient’s parents will benefit because there will
ideally be a decreased medical bill as a result of fewer tests being ordered, and also because their
newborn will receive the treatment he/she needs more quickly with less long-term consequences.
Lastly, insurance companies will benefit as a result of the decreased costs of diagnosis and
treatment.
6.4 Health and Safety Concerns
Health and safety is a very important topic in research to ensure that there is no unnecessary risk
associated with the chemicals used or experiments conducted. Our group underwent extensive
health and safety training at both SCU and Stanford before being able to enter the laboratory
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space. Additionally, we followed the proper safety policies and procedures throughout the
duration of our experiments as outlined by each university. Our group kept a watchful eye
throughout our time in the lab and promptly addressed any safety hazards.
6.5 Political Concerns
With our Senior Design Project addressing biomarker discovery and eventually fulfilling an
unmet diagnostic need, it is unlikely that our device will initially be covered in health insurance
plans. We hope that legislation is introduced that will require health insurance companies to
cover the cost. Currently, there is a strong social backing to improve neonatal care and protect
defenseless beings. Hopefully, this social backing can be translated into political pressure to
broaden coverage for neonates with impaired conditions.
6.6 Environmental Concerns
Our Senior Design project aimed to be highly cognizant of the material we used during our
experiments and aimed to not have a significant and/or toxic effect on the environment. We
reused materials whenever possible to reduce waste, planning our methods around this. Part of
the team’s training to work in the Stanford lab was being able to identify the characteristics of
different chemicals that had indications or contraindications to store in the same container.
Additionally, the team made sure to properly dispose of all liquid waste from ELISA, cell
culturing, and other experiments and to never discard down a sink drain.
6.7 Sustainability
The sustainability of our project is closely related to the environmental impact it has. Our project
wants to have a minimal waste footprint and hopes to use material that can be easily regenerated
and replenished. In the long run, our project will promote a more sustainable treatment path for
neonates with NEC because of the decreased number of ineffective tests and treatments as a
result of rapid diagnosis. Finally, the source of our proposed biomarker, stool, is much more
sustainable than blood-sourced.
6.8 Social Concerns
With infants being defenseless beings, there is a strong social backing to support them and
promote their well-being. As such, there does not appear to be any negative social concern
surrounding this project, but rather support to continue its work and improve neonatal diagnosis
and care. Additionally, there is no concern surrounding withholding or delivering improper
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treatment to neonates as a result of experiments as we are only aiming to create a noninvasive
biomarker detection route for diagnosis.

38

References
1. Children’s Hospital of Los Angeles. Necrotizing Enterocolitis. Children’s Hospital of Los
Angeles. Retrieved June 14, 2019, from https://www.chla.org/necrotizing-enterocolitis
2. Niño, D. F., Sodhi, C. P., & Hackam, D. J. (2016). Necrotizing enterocolitis: new insights
into pathogenesis and mechanisms. Nature reviews Gastroenterology & hepatology, 13( 10),
590.
3. Stanford Children’s Health. Necrotizing Enterocolitis. Lucile Packard Children’s Hospital.
Retrieved June 16, 2019, from
https://www.stanfordchildrens.org/en/topic/default?id=necrotizing-enterocolitis-90-P02388
4. Center for Diseases Control and Prevention. Premature Births. Center for Disease Control
and Prevention. Retrieved June 14, 2019, from
https://www.cdc.gov/features/prematurebirth/index.html
5. Sinclair, T., Tao, G., Liu, B., Zhang, R., Lu, C. T., & Sylvester, K. G. (2016). Necroptosis is
Associated with Development Dependent Enterocyte Death in a Mouse Model of Intestinal
Injury and Human Necrotizing Enterocolitis. Journal of the American College of Surgeons,
223(4), e157-e158.
6. Behrman, R. E., & Butler, A. S. (2007). Mortality and acute complications in preterm infants.
In Preterm Birth: Causes, consequences, and prevention. National Academies Press (US).
7. Neu, J., & Walker, W. A. (2011). Necrotizing enterocolitis. New England Journal of
Medicine, 364(3), 255-264.
8. Spencer, A. U., Kovacevich, D., McKinney-Barnett, M., Hair, D., Canham, J., Maksym, C.,
& Teitelbaum, D. H. (2008). Pediatric short-bowel syndrome: the cost of comprehensive
care. The American journal of clinical nutrition, 88(6), 1552-1559.
9. Sylvester, K. G., Kastenberg, Z. J., Moss, R. L., Enns, G. M., Cowan, T. M., Shaw, G. M., ...
& Jelliffe-Pawlowski, L. L. (2017). Acylcarnitine profiles reflect metabolic vulnerability for
necrotizing enterocolitis in newborns born premature. The Journal of pediatrics, 181, 80-85.

39

10. Lin, J., Nafday, S. M., Chauvin, S. N., Magid, M. S., Pabbatireddy, S., Holzman, I. R., &
Babyatsky, M. W. (2002). Variable effects of short chain fatty acids and lactic acid in
inducing intestinal mucosal injury in newborn rats. Journal of pediatric gastroenterology and
nutrition, 35(4), 545-550.
11. Graspeuntner, S., Waschina, S., Künzel, S., Twisselmann, N., Rausch, T. K.,
Cloppenborg-Schmidt, K., ... & Baines, J. F. (2018). Gut dysbiosis with Bacilli dominance
and accumulation of fermentation products precedes late-onset sepsis in preterm infants.
Clinical Infectious Diseases.
12. National Center for Biotechnology Information. PubChem Database. Butyrate, CID=104775,
Retrieved June 16, 2019, from https://pubchem.ncbi.nlm.nih.gov/compound/Butyrate
13. Sylvester, K. G., Ling, X. B., Liu, G. Y. G., Kastenberg, Z. J., Ji, J., Hu, Z., ... & Ehrenkranz,
R. A. (2014). Urine protein biomarkers for the diagnosis and prognosis of necrotizing
enterocolitis in infants. The Journal of pediatrics, 164( 3), 607-612.
14. Vergauwen, H. (2015). The IPEC-J2 cell line. In The Impact of Food Bioactives on Health
(pp. 125-134). Springer, Cham.
15. American Type Culture Collection. Caco-2 [Caco2] (ATCC® HTB-37™). Retrieved June
15, 2019, from https://www.atcc.org/products/all/HTB-37.aspx
16. American Type Culture Collection. HuTu 80 (ATCC® HTB-40™). Retrieved June 15, 2019,
from https://www.atcc.org/products/all/HTB-40.aspx
17. Stoll, B. J., Hansen, N. I., Bell, E. F., Walsh, M. C., Carlo, W. A., Shankaran, S., ... & Das,
A. (2015). Trends in care practices, morbidity, and mortality of extremely preterm neonates,
1993-2012. Jama, 314( 10), 1039-1051.
18. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., ...
& Hengartner, M. (2009). Classification of cell death: recommendations of the Nomenclature
Committee on Cell Death 2009. Cell death and differentiation, 16( 1), 3.
19. American Type Culture Collection. HT-29 (ATCC® HTB-38™).
https://www.atcc.org/products/all/HTB-38.aspx#generalinformation
20. American Type Culture Collection. HIEC-6 (ATCC® CRL-3266™). Retrieved June 16,
2019, from https://www.atcc.org/products/all/CRL-3266.aspx
40

21. Idriss, H. T., & Naismith, J. H. (2000). TNFα and the TNF receptor superfamily:
Structure-function relationship (s). Microscopy research and technique, 50( 3), 184-195.
22. Lipopolysaccharides - Structure, Function and Application. (n.d.). Retrieved June 16, 2019,
from
https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/lipopolysa
ccharides.html
23. Sies, H. (2017). Hydrogen peroxide as a central redox signaling molecule in physiological
oxidative stress: oxidative eustress. Redox biology, 11, 613-619.
24. Halliwell, B., Long, L. H., Yee, T. P., Lim, S., & Kelly, R. (2004). Establishing biomarkers
of oxidative stress: the measurement of hydrogen peroxide in human urine. Current
medicinal chemistry, 11( 9), 1085-1092.
25. American Type Culture Collection. HIEC-6 (ATCC® CRL-3266™). Retrieved June 15,
2019, from
https://www.atcc.org/en/Products/Cells_and_Microorganisms/By_Tissue/Intestine_Small/CR
L-3266.aspx#culturemethod
26. American Type Culture Collection. HT-29 (ATCC® HTB-38™). Retrieved June 15, 2019,
from https://atcc.org/Products/All/HTB-38.aspx#culturemethod
27. Gill, R. K., Alrefai, W. A., Maher, D., Kumar, A., Dudeja, P. K., Singh, V., ... & Saksena, S.
(2011). Butyrate Decreases Intestinal Serotonin Transporter Expression via Epigenetic
Mechanisms. Gastroenterology, 140(5), S-657.
28. Belizário, J., Vieira-Cordeiro, L., & Enns, S. (2015). Necroptotic cell death signaling and
execution pathway: lessons from knockout mice. Mediators of inflammation, 2015.
29. National Center for Biotechnology Information. PubChem Database. Phenol red, CID=4766,
Retrieved June 16, 2019, from https://pubchem.ncbi.nlm.nih.gov/compound/Phenol-red
30. Mackenzie, C. G., Mackenzie, J. B., & Beck, P. (1961). The effect of pH on growth, protein
synthesis, and lipid-rich particles of cultured mammalian cells. The Journal of Cell Biology,
9(1), 141-156.

41

31. Fitzgerald, R. C., Omary, M. B., & Triadafilopoulos, G. (1997). Acid modulation of HT29
cell growth and differentiation. An in vitro model for Barrett's esophagus. Journal of cell
science, 110(5), 663-671.
32. Cairns, R. A. (2015). Drivers of the Warburg phenotype. The Cancer Journal, 21(2), 56-61.
33. Kriesberg, R. A. and Wood, B. C. Drug and chemical-induced metabolic acidosis. Clin
Endocrinol Metab.  1983 Jul;12(2):391-411.
34. Rabiee, S., Tavakol, S., Barati, M., & Joghataei, M. T. (2019). Autophagic, apoptotic, and
necrotic cancer cell fates triggered by acidic pH microenvironment. Journal of cellular
physiology, 234(7), 12061-12069.
35. Wojtkowiak, J. W., & Gillies, R. J. (2012). Autophagy on acid. Autophagy, 8( 11),
1688-1689.
36. Rabiee, S., Tavakol, S., Barati, M., & Joghataei, M. T. (2019). Autophagic, apoptotic, and
necrotic cancer cell fates triggered by acidic pH microenvironment. Journal of cellular
physiology, 234(7), 12061-12069.
37. Fadhel, A. Z., Pollet, P., Liotta, C. L., & Eckert, C. A. (2010). Combining the benefits of
homogeneous and heterogeneous catalysis with tunable solvents and near critical water.
Molecules, 15(11), 8400-8424.
38. Charbonneau, M. R., Blanton, L. V., DiGiulio, D. B., Relman, D. A., Lebrilla, C. B., Mills,
D. A., & Gordon, J. I. (2016). A microbial perspective of human developmental biology.
Nature, 535(7610), 48.

42

Appendix
Appendix A. Gantt chart summarizing our project timeline.

Fall Quarter

Winter
Break

Winter
Quarter

Spring Quarter

Stanford
interviews,
selection, and
approval for
project
Complete
lab safety
and HIPAA
training
Conducting experiments at Stanford’s lab (2-3 days per week)
Senior
Design
presentation
Writing Thesis
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Appendix B. Detailed Profile on Four Initial Factors Plated
(1) TNF-alpha:
TNF-alpha is a proinflammatory cytokine involved in many different cell signalling pathways to
necrosis or apoptosis [2, 21]. With the onset of acute inflammation, macrophages and white
blood cells produce and secrete TNF-alpha into the blood [21]; in the literature it is noted to be a
potentially useful blood biomarker for NEC as an inflammatory disease [2].
(2) LPS:
LPS is an endotoxin existing on the surface of gram-negative bacteria to protect them from
damage [22]. In humans, LPS plays a role in sepsis; in mammalian cells, it brings about a strong
immune response [22].
(3) H2O2:
As a product of the mitochondrial respiratory chain, H2O2 is involved in cellular metabolism
[34]. Abnormally high levels are classified as a source of oxidative stress, which can damage
cells and biomolecules [23]. Thus, it can sometimes be used as a biomarker for oxidative stress,
and can be detected in urine [24].
(4) Butyrate:
Butyrate, the anion of the short-chain fatty acid called butyric acid, is a fermentation product of
bacteria found in the human colon. Butyrate is thought to play a role in maintaining a healthy
colon, perhaps by removing damaged cells [12]; it has recently been confirmed to induce
necroptosis [5]. Healthy colorectal epithelial cells easily absorb and use butyric acid as an energy
source [12], but in NEC babies, who may have an abnormal fatty acid metabolism [9], this
beneficial process may become dysfunctional.
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Appendix C. Additional Laboratory Protocols
1. Modified ELISA to Measure Insoluble Protein, Cytokeratin-8 (CK8), in Stool
1. 96-well MaxiSorp™ Nunc-immuno module plates (Thermo Fisher Scientific) were
pre-coated with HT-29 cells containing CK8 (protein concentration 10 μg/ml) in coating
buffer (PBS 50 μl/well) overnight at 4°C.
2. 25 μl samples and standards were diluted in PBS/EDTA buffer and mixed with 25μl
blocking buffer (5% skim milk/PBST/2% NP40: 0.25 g milk + 4.5 ml PBST + 0.5 ml
20% NP40) for 30 min with shaking.
3. 50 μl anti-CK8 antibody (Troma-1, 1:4,000, 4 ml PBS/EDTA + 1 μl Troma-1) was added
to each tube and incubated at RT for 1 h with shaking.
4. The pre-coated plates (1) were washed 3 times in 1X PBS buffer. Premixed samples with
antibody (2,3) were transferred to each well of the pre-coated plates and incubated for 1 h
at RT with shaking (100 μl/well), followed by washing 3 times in PBST buffer.
5. 100 μl HRP (horseradish peroxidase)-conjugated goat anti-rat antibodies
(Immnuoreagents lnc.) diluted 1:5,000 (v/v) in PBST/5% skim milk buffer was added per
well and incubated at RT with shaking for 30 min.
6. Plates were washed 5 times and visualized by incubating in TMB substrate kit (Thermo
Fisher Scientific, 100 μl/well) for 15 min.
7. Subsequently, 100 μl 2 M H2SO4 was added to each well to stop color development.
8. The plates were read at 450 nm with reference filter at 620 nm using the SpectraMax®
i3x multi-mode microplate reader (Molecular Devices, LCC. CA, USA).
9. Final concentrations were obtained using the standard curve method.
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Appendix D. Slides from Senior Design Presentation
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